In the absence of definitive evidence to speak to a best approach, I and many other thoracic oncologists favor treating these cases on an individual basis. The fact that we are seeing more patients doing well, without progression, potentially years after having come off of immune checkpoint inhibito...

I generally recommend stopping treatment after 2 years of checkpoint inhibition. I fully agree that there is a paucity of data as it relates to the duration of checkpoint inhibitor therapy in cancer. However some general trends across cancer types are emerging. For example, the quality of respo...

Based on available and emerging data, it seems that continuing beyond 2 years may be beneficial. However, potential toxicity and impact on patient's QoL need to be weighed against benefit. There is data to support retreatment with immunotherapy in patients who progress while off of all treatment aft...

Personally, I would take the opportunity to see if we can learn from whatever this patient or you chose to do by learning the value of a measurement of Minimal Residual disease for decision making. The most sensitive assay which can detect 3 cells in 100,000 in solid tumors has just been published i...

I would stop treatment only for those patients are in CR even before two years of treatment. If active disease at two years, I would recommend to continue IO.